Pictura Bio

Pictura Bio is pioneering a novel point-of-care diagnostic platform called PIC-ID, which aims to deliver pathogen identification results in approximately one minute. The technology combines a single-reagent assay, a compact fluorescence microscopy reader (VISTA), and AI-powered image analysis to provide rapid, multiplexed infectious disease testing. Targeting the significant delays and costs associated with traditional lab tests, the company seeks to transform emergency and primary care by enabling immediate, data-backed treatment decisions. Backed by investors like Ahren, IQ Capital, and Science Creates, Pictura Bio is developing its suite of technologies to scale diagnostics directly to frontline healthcare settings.

PIC-ID platform combining a single universal reagent for pathogen detection, the VISTA Reader (compact fluorescence microscopy hardware), and AI/computer vision software for rapid image analysis and multiplexed pathogen identification in approximately one minute.

Pictura Bio competes in the rapid diagnostic market against established lateral flow antigen tests (fast but less sensitive/multiplexed) and compact molecular/PCR systems (accurate but often slower and more expensive). Its key differentiator is the promised combination of extreme speed (~1 minute), multiplexing capability, and a simplified assay process using a single reagent, powered by AI-driven image analysis rather than traditional biochemistry.